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A FUNCTIONAL POLYMORPHISM IN THE CATECHOL-O
METHYLTRANSFERASE (COMT) GENE IS ASSOCIATED
WITH OA-RELATED PAIN
J.B. van Meurs, A.G. Uitterlinden, L. Stolk, H.A. Pols,
S.M. Bierma-Zeinstra
Erasmus MC, Rotterdam, The Netherlands
Purpose: Joint complaints are very common in the elderly and
a major reason for disability and reduced quality of life. It is
clear that radiographic evidence of joint damage predisposes to
joint pain, but the severity of the joint damage is only weakly
related to the severity of the pain experienced. Whether a person
develops chronic pain or not in a (radiographically) damaged
joint is partly determined by genetic variations and heritability
estimates for joint pain range between 35-65%. Thus, persons
that develop chronic pain might possess a combination of genetic
variations that increase their sensitivity to pain. The COMT-gene
(catechol-O-methyltransferase) is involved in pain perception;
inhibition of COMT was shown to increase pain sensitivity. The
aim of our study was to examine whether a well-known functional
polymorphism in the COMT-gene (Val158Met) inﬂuences OA-
related pain.
Methods: We studied 3033 individuals aged 55 years and over
from a large population-based study (Rotterdam study). All sub-
jects were scored for radiographic hip OA (deﬁned as Kellgren&
Lawrence ≥2) as well as hip pain (assessed by interview). Geno-
types of the Val158Met polymorphism of the COMT-gene were
assessed by Taqman.
Results: Allele frequency of the low activity allele of the COMT
gene (158Met) was 55%. In the total population, the COMT
variant was not associated with hip pain. However, when we
selected individuals who had radiographically deﬁned hip-OA (n
=288), we observed that carriers of the 158-Met variant had
2.7 times higher risk (95% CI: 1.2-6.1; p=0.02) for hip pain as
compared to the ValVal-genotype. This effect was fully driven
by the women (n =171). Female carriers of the 158-Val allele
were 4.9 times more likely to have pain (95% CI: 1.6-14.8;
p=0.005) while radiographical damage to the hip was present
in both genotype groups. These results were not affected by
adjustments for age and BMI, two well known risk factors for OA.
Conclusions: The low activity allele of the COMT-gene (158Met)
is associated with increased hip pain in individuals with radiologi-
cal damage of the hip. This ﬁnding is in line with previous studies
in mice which showed that inhibition of COMT increases pain
sensitivity, presumably via the β2/3 adrenergic pathways. Our
ﬁndings need to be replicated in other large study populations,
but might have important clinical implications, since the preva-
lence of the COMT low activity allele is very high. Our results
also highlight the importance of studying joint related pain as a
separate trait in genetic epidemiological studies.
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DIFFERENTIAL EXPRESSION OF CALCITONIN
GENE-RELATED PEPTIDE AND P2X3 IN JOINT-SPECIFIC
AFFERENT NEURONES, IN THE RAT
MONO-IODOACETATEMODEL OF DEGENERATIVE
JOINT DISEASE
S.P. Ivanavicius, A. Ball, R. Webster, S. Read, F. Murray
Astrazeneca, Respiratory and Inﬂammation Research Area,
Alderley Park, United Kingdom
Purpose: The purine receptor P2X3 is almost exclusively ex-
pressed on non-peptidergic afferent neurones, a subtype of noci-
ceptors normally absent from the rat knee joint. During the course
of some animal models of joint pain, P2X3-immunoreactivity
(IR) is increased in calcitonin gene-related peptide (CGRP)-
expressing neurones and has therefore been implicated in as-
sociated nociceptive pathways. In the mono-iodoacetate (MIA)
model of degenerative joint disease, which exhibits histopatho-
logical similarities to osteoarthritis (OA), CGRP-expression in-
creases in joint-speciﬁc afferent neurones. Thus, for the current
study we aimed to determine weather or not any changes in
CGRP-expressing joint afferents are associated with increased
expression of P2X3 in the lumbar (L)4 dorsal root ganglion (DRG)
at days 3 and 14 post-disease induction.
Methods: Male Wistar rats (180-200g) were anaesthetised and
given intra-articular (i.a.) injections of ﬂuoro-gold (FG; 2%, 5 ul)
to label joint afferent neurones. Seven days later (day 0) ani-
mals were anaesthetised and given i.a. injections of MIA (1mg
in 20ul) or saline (20ul) (n = 8 per group). Hind limb weight
bearing measurements were recorded at regular intervals prior
to and throughout the study using an incapacitance meter. On
days 3 and 14 post-MIA, animals were anaesthetised following
weight bearing, perfused transcardially with 4% paraformalde-
hyde and ipsilateral L4 DRG removed (n = 4 per group, per
time point). Serial sections (14 um) were cut and labelled using
primary antibodies, anti-CGRP and anti-P2X3 and secondary an-
tibodies, Alexa Fluor 488 and 594, respectively. Weight bearing
data is presented as a percentage ratio (ipsilateral/contralateral),
CGRP and P2X3-IR are expressed as the mean percentage co-
localization with FG-labelled cells (± SEM). Animal experiments
were carried out in accordance with the UK Animals (Scientiﬁc
Procedures) Act, 1986 and related guidelines.
Results: Ipsilateral hind limb weight bearing was signiﬁcantly
reduced in MIA treated animals as compared to saline controls
on days 3 and 14 (Student’s t-test, P <0.001 and P <0.01,
respectively). FG-CGRP co-localization in L4 DRG was signiﬁ-
cantly greater at day 3 in the MIA group compared to the saline
group, 65.9% (±2.9%) and 45.5% (±5.0%), respectively (Mann
Whitney U-test, P <0.05). At day 14 there was no signiﬁcant
difference in FG-CGRP co-localization between groups. No sig-
niﬁcant difference in FG-CGRP-P2X3 co-localization and total
CGRP-P2X3 co-localization was measured between groups in
L4 DRG at any time point.
Conclusions: We have identiﬁed increased CGRP-IR in joint-
speciﬁc afferents in L4 DRG at day 3, but not day 14, following
i.a. injection of MIA. The day 3 increase in CGRP-expression in
joint afferents is comparable to previous ﬁndings observed at day
28 in the same model. The return to baseline levels of CGRP
at day 14 may imply a biphasic expression proﬁle for CGRP in
joint afferents, in the MIA model. During the early stages of the
MIA model (day 3) there is an inﬂammatory component, which
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may be mediated, in part, by increased CGRP-expression. At
latter stages (day 28) there is considerable tissue remodelling
within the joint where CGRP is known to contribute. Whereas,
during the intermediate stages of the model (day 14) the inﬂam-
matory component has subsided and tissue remodelling is not
as pronounced as latter stages. The absence of any differential
CGRP-P2X3 co-localization in total and joint-speciﬁc afferents,
between groups and over time, suggests that P2X3 does not
have a primary role in the pathophysiology associated with the
ﬁrst 14 days of the MIA model.
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TYPE IX COLLAGEN KNOCKOUT IS ASSOCIATED WITH
ALTERED GAIT BEHAVIORS AND MECHANICAL
ALLODYNIA IN MICE
K.D. Allen, T.M. Grifﬁn, W.C. Wetsel, R.M. Rodriguiz,
L.M. Boyd, L.A. Setton
Duke University, Durham, NC
Purpose: Mice with inactivation of the Col9a1 gene (type IX
collagen) prematurely develop osteoarthritis and intervertebral
disc degeneration. Measures of gait, motor coordination, and no-
ciceptive responses are reﬂective of disease pathology in other
models, but have not been well-studied for genetic models with
joint degeneration. Our objective was to determine if these mea-
sures can serve as minimally invasive biomarkers in a mouse
model of joint disease. Gait, motor coordination, and pain sen-
sitivity were evaluated in 12 month-old Col9a1 knockout (KO)
and wild-type (WT) mice to evaluate differences in functional and
symptomatic measures.
Methods: Gait data were acquired from high-speed videos
(Phantom V4.2, 250 fps) of 10 KO and 10 WT mice freely
exploring a gait arena (unprompted) or responding to a gentle
brush (prompted). Nose, tail, and paw pixel coordinates were
used to calculate velocity, stride length, step width, and per-
centage of a stride a given limb is in ground contact. Rotarod
(Med-Associates) tests were conducted to test motor coordina-
tion. Mice were ﬁrst placed on an accelerating rotorod (4-40
rpm/5-min); the next day, mice were tested at steady speed (16
rpm for 5-min). Four trials separated by 30 min were given each
day. Latency to fall was recorded. Von Frey ﬁlaments (Stoelting,
sizes 2.83-4.56) calibrated to known forces were applied to the
hind-paw plantar surfaces to test mechanical allodynia. Each
ﬁlament was applied to the left then right paw, and presence
of a withdrawal response was recorded (4 trials). Force at 50%
likelihood of paw withdrawal was determined by ﬁtting a sigmoid
function to the withdrawal frequency versus ﬁlament force. To
test thermal sensitivity, mice were placed on a 52.0 ± 0.20C
hot-plate (Columbus Instruments) and latency to paw ﬂick was
recorded. From the hot-plate, mice were placed in a tail-ﬂick
apparatus (Columbus Instruments) and the mid-portion tail was
exposed to a radiant light source. The latency for tail withdrawal
was scored. Both tests were repeated at 0, 15, 30, 60, 90, 120,
and 240 mins.
Results: Gait studies revealed Col9a1 KO mice employ lower
unprompted velocities, but when prompted, achieve velocities
comparable to WT controls (Figure 1).
KOs also have wider hind-limb step widths, take shorter strides,
and their hind-paws remain in ground contact for a larger per-
centage of the stride in unprompted trials; no genotype differ-
ences were observed on prompted trials. In accelerating rotarod
tests, KOs show few deﬁciencies, but motor coordination and
endurance were deﬁcient at steady speed (Figure 2).
KOs were also more sensitive to mechanical, but not thermal,
stimuli (Figure 3).
Conclusions: These data for gait behaviors and mechanical
nociception indicate that Col9a1 KO mice self-select slower, less
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strenuous gaits, perhaps due to increased mechanical sensitivity.
When challenged to perform at higher activity levels, KO mice
can do so in short sustained bursts (prompted gait), but may
not have sufﬁcient endurance to engage in more strenuous
activities (rotarod). Alterations in response to mechanical, but
not thermal, stimuli suggest these changes may be driven by
speciﬁc central mechanisms. Additional studies are required to
determine whether the joint or spine pathologies contribute to
the observed gait and pain changes.
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NAPROXEN AND A MATRIX METALLOPROTEINASE
INHIBITOR BOTH REDUCE WEIGHT BEARING
ASYMMETRY, INDICATIVE OF BEHAVIOURAL PAIN, IN
THE RAT MENISCAL TRANSECTION MODEL OF
OSTEOARTHRITIS
J. Bowyer, R. Webster, R. Westwood, C. Day, C. Stannard,
S.J. Read, R.A. Maciewicz
AstraZeneca, Macclesﬁeld, United Kingdom
Purpose: It has been postulated that the development of chon-
droprotective agents will be of little consequence to patients
unless they manifest improvements in quality of life measures.
The rat meniscal transection (MT) model demonstrates cartilage
erosion, consistent with some facets of human pathology and
this joint destruction correlates with weight bearing asymmetry,
indicative of behavioural pain. The aim of this study was to in-
